<DOC>
	<DOC>NCT02532868</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of MK-0457(VX-680), an Aurora kinase inhibitor, in participants with advanced solid tumors. Bioavailability of the oral formulation will also be assessed. The primary study hypothesis is that administration of MK-0457 is sufficiently safe and tolerated to permit further study.</brief_summary>
	<brief_title>A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)</brief_title>
	<detailed_description />
	<criteria>Patients who are at least 18 years of age with recurrent or nonresponsive solid tumors, or cancers for which standard therapy does not exist. Patients who have had treatment with any investigational therapy within the past 30 days. Patients who have certain types of blood cancers such as leukemia or lymphoma. Patients who have uncontrolled congestive heart failure (CHF), chest pains, or had a heart attack within the past 3 months, or have undergone bone marrow or stem cell transplantation. Patient is pregnant or nursing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>